Genmab — April 2018
-
Men mærkeligt nok ikke noget om dette studie https://www.clinicaltrials.gov/ct2/show/NCT02951819?term=daratumumab+cybord&rank=3 , der havde Primary Completion Date 8. marts.
-
Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting https://globenewswire.com/news-release/2018/04/25/1487380/0/en/Genmab-Announces-Data-to-be-Presented-at-2018-ASCO-Annual-Meeting.html
-
Det har Winkel talt om ved flere lejligheder. Da der er et udækket behov for et medikament i metastatisk LMHK, vil muligheden være til stede, hvis data er gode nok. Men studiet er end ikke begyndt at rekruttere https://www.clinicaltrials.gov/ct2/show/NCT03438396?term=tisotumab+vedotin&rank=3 Så tidligst 2021 er hvad jeg har hørt.
-
https://clinicaltrials.gov/ct2/show/NCT03357952?term=JNJ-63723283&rank=2 Pd1 plus dara har primary completion date 15. Marts i år....
-
Pudsigt, i pressemeddelelsen skriver Genmab at det er et fase 2/3 studie. På ct står det som fase 1?? https://clinicaltrials.gov/ct2/show/NCT03357952?term=mmy2036&rank=1 Men det er måske det, de mener med et multi-fase-studie. Og at effekt-delen i part 3 er nok til at file på? Der er jo pænt mange pts med.
-
Holdt foredrag i Svinningehallen her til aften. Genmab er stadig en folkeaktie.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind